Search PubMed⌕ Search

Biomedical subjects

L V Stakhovskaia

Publications and source records attributed to L V Stakhovskaia.

At least 19 recordsLinked to original sources
PubMed2006

[Batroxobin in patients with ischemic stroke in the carotid system (the multicenter study)].

A randomized placebo-controlled study has been carried out in 3 Moscow hospitals. A sample included 90 patients who survived hemispheric ischemic stroke caused by pathology in the internal carotid artery 72 h before the treatment. Forty-five patients were given standard (basic) therapy and 45 patients received adjuvant batroxobin intravenously by 1,0 ml (10BU) drops on day 1, 3 and 5 and by 0,5 ml (5BU) drops on day 7 and 9 after admitting in a hospital. Assessment of the patients' state was conducted before the treatment, on day 3, 6 and 15. The European Stroke Scale was used to measure severity of clinical symptoms. The results suggest efficacy of batroxobin the use of which provides rapid good results, especially improvement in movement disorders. The use of this drug is accompanied by defibrinating effect. The drug is well tolerated.

Batroxobin↗
PubMed2005

[The efficacy of surgical and conservative methods in secondary prevention of carotid ischemic stroke].

A comparative analysis of the efficacy of surgical and conservative methods in secondary prevention of carotid ischemic stroke has been conducted in patients with clinical symptoms of acute ischemic brain lesions (carotid artery stenosis less than 70%). The results of the 3-year follow-up study revealed that carotid endarterectomua is a method of choice. Comparing to conservative therapy, it allows a reduction of the absolute risk of secondary ischemic episode development to 4% (57% for conservative therapy) and of the relative risk--to 0.07 (0.77 for conservative therapy). The necessity of antiaggregate therapy that enables increased percentage of strokes prevented is proved. Comparing to aspirin, clopidogrel is a drug of choice contributing to the regress of thrombotic layers in the cases of restenosis development in the area of sutures after the interventions using special patches.

Aged↗
PubMed2005

[Ethnic and genealogical aspects of cerebral stroke in Izhevsk city].

To study hereditary predisposition to stroke in main ethnic groups of Izhevsk, 210 patients born in ethnically homogenous marriages have been examined and the data on state of health of 1701 relatives over 40 years old have been obtained. A role of hereditary factor in development of stroke was revealed. Also, there were ethnic differences related to a prevalence of carbohydrate-lipid metabolism disorder in patients of the Tartar group comparing to Udmurt and Russians.

Adult↗
PubMed2004

[Possibilities and perspectives of berlition usage in the treatment of alcohol polyneuropathy].

A comparison study of efficacy and tolerability of the drug berlition 300 oral and berliton 300 U and vitamin B1 has been conducted in 56 patients with alcohol polyneuropathy (15 female, 41 male, mean age 42.6 years). The key mechanisms of berlition action are increasing of endoneural blood flow, strengthening of antioxidant system functioning and reduction of "oxidative stress" intensity; improvement of glucose consumption and restoring of nerve energetic balance as well as intensification of nerve growth factor releasing and nerve growth acceleration after its experiment cutting or squeezing. Usage of berlition in the cohort studied was accompanied by a positive dynamics of both subjective and objective clinical symptoms. Comparing to vitamin B1, the drug was significantly more effective by clinical and electrophysiological indices. Berlition therapy is tolerable and safe. The results of the study confirm an assumption of berlition efficacy in alcohol polyneuropathy and allow to recommend the drug for a wide clinical application.

Adult↗
PubMed2004

[A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke].

The aim of the study was to assess safety and efficacy of the neuroprotective drug Cerebrolysin in acute ischemic stroke. Thirty-six patients with ischemic stroke in carotid artery territory aged 45-85 years, were eligible for inclusion in the trial if they were admitted to the hospital within the first 12h after stroke onset. Patients were randomly and blindly assigned to placebo (n = 12) or 1 or 2 dosages of Cerebrolysin: 10 ml/d (n = 12) and 50 ml/d (n = 12) for 10 days with concomitant standard basic treatment in each group. A quantitative time-related analysis of the dynamics of neurological deficit revealed the tendency towards acceleration of improvement assessed by the Clinical Global Impression Scale and NIHSS in both Cerebrolysin groups by 30 day of the treatment. The significant reduction in the volume of MRI ischemic focus was shown in both Cerebrolysin groups (p < 0.05 vs Placebo) on day 3. Acute pharmacological test revealed a decrease (p < 0.05 vs Placebo) of the size and spread of delta and theta foci in 72.7% patients, receiving 50 ml/d of Cerebrolysin. In none of the cases, Cerebrolysin treatment provoked any paroxysmal activity on EEG. The trial demonstrated safety, efficacy and good tolerability of hige-dose Cerebrolysin in the treatment of ischemic stroke.

Acute Disease↗
PubMed2003

[Epidemiology of stroke in Russia].

Using a register approach, an epidemiologic survey of stroke in Russia was conducted according to a program specially worked out. A total sample studied included 2,398,498 subjects, aged 25 years and older from 19 Russian cities. Overall, 9998 new cases of acute blood supply disturbances were registered for a one-year period. In 2001, stroke morbidity was found to reach 3.36 per 1000 persons, mortality rate--1.28, lethality--40.37% (61.4% in hemorrhagic and 21.8% in ischemic stroke). The highest morbidity was observed in the North-West regions (7.43 per 1000), in some cities of middle areas (5.37) and in the Far East (4.41), percentage of hemorrhagic stroke being higher as well. It is concluded that a longitudinal register for obtaining data on mortality dynamics and evaluation of efficacy of improved medico-social care program is needed.

Adult↗
PubMed2001

[Neurophysiological characteristics of transitory global amnesia syndrome].

Twenty seven patients with transitory global amnesia (TGA) in acute and remote (after 7 and more days) stages and 31 dyscircular encephalopathy patients with subjective memory disturbances (control group) have been examined. According to electroencephalographical (EEG) data and wave P300 cognitive evoked potential evaluation, the differences in the beta 1-activity between these groups have been found. beta 1-Activity expression on EEG correlated in different ways with latent P300 periods, increasing together with latent period (r = 0.43) in control group and decreasing in TGA (r = -0.23). The most distinct, changes were expressed in central cerebral regions. The authors hold that the relationship between changes of EEG and cognitive evoked potential in acute and remote TGA stages, as well as in control group, indicate functional character of TGA syndrome, being unrelated to cerebral structure damage.

Aged↗